Patent ID: 11963955
Assignee: TEXAS SOUTHERN UNIVERSITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 1:
2. The method of claim 1, wherein inhibiting or ameliorating a SARS-CoV-2 infection comprises one or more of:
inhibiting or ameliorating one or more SARS-CoV-2 infection induced cytopathic effects;
inhibiting or disrupting physical interaction of angiotensin converting enzyme 2 (ACE2) with SARS-CoV-2 spike glycoprotein;
blocking a pathway of SARS-CoV-2 entry into human cells via modulation of angiotensin converting enzyme 2 (ACE2) interaction with receptor binding domain protein of SARS-CoV-2; or
blocking angiotensin converting enzyme 2 (ACE2) exopeptidase function, thereby inhibiting ACE2 exopeptidase interaction with SARS-CoV-2 spike glycoprotein.